These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 7840511)

  • 21. [Study of the cytosolic concentrations of the tissue poly-peptide specific (TPS) antigen in infiltrating ductal carcinomas of the breast. Positive relationship with hormone dependency and negative with cellular proliferation].
    Ruibal A; Arias JI; Resino C; Lapeña G; Schneider J; Tejerina A
    Rev Esp Med Nucl; 2001 Aug; 20(5):365-8. PubMed ID: 11470070
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic value of pS2 protein and receptors for epidermal growth factor (EGF-R), insulin-like growth factor-1 (IGF-1-R) and somatostatin (SS-R) in patients with breast and ovarian cancer.
    Foekens JA; van Putten WL; Portengen H; Rodenburg CJ; Reubi JC; Berns PM; Henzen-Logmans SC; van der Burg ME; Alexieva-Figusch J; Klijn JG
    J Steroid Biochem Mol Biol; 1990 Dec; 37(6):815-21. PubMed ID: 2178364
    [TBL] [Abstract][Full Text] [Related]  

  • 23. pS2 expression in infiltrating ductal carcinoma of the breast correlates with oestrogen receptor positivity but not with histological grade and lymph node status.
    Looi LM; Azura WW; Cheah PL; Ng MH
    Pathology; 2001 Aug; 33(3):283-6. PubMed ID: 11523925
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enzyme-linked immunosorbent assay of pS2 in breast cancers, benign tumors, and normal breast tissues. Correlation with prognosis and adjuvant hormone therapy.
    Predine J; Spyratos F; Prud'homme JF; Andrieu C; Hacene K; Brunet M; Pallud C; Milgrom E
    Cancer; 1992 Apr; 69(8):2116-23. PubMed ID: 1544118
    [TBL] [Abstract][Full Text] [Related]  

  • 25. pS2 is an independent prognostic factor for post-relapse survival in primary breast cancer.
    Jansen RL; Hupperets PS; Arends JW; Joosten-Achjanie SR; Volovics A; Hillen HF; Schouten HC
    Anticancer Res; 1998; 18(1B):577-82. PubMed ID: 9568180
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi.
    MacGrogan G; Mauriac L; Durand M; Bonichon F; Trojani M; de Mascarel I; Coindre JM
    Br J Cancer; 1996 Nov; 74(9):1458-65. PubMed ID: 8912545
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PS2 protein in breast carcinomas: cut-off value of estrogen-regulated expression.
    Nikolić-Vukosavljević D; Grujić-Adanja G; Janković R; Nesković-Konstantinović Z; Branković-Magić M
    Neoplasma; 2001; 48(1):1-6. PubMed ID: 11327531
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunoradiometric detection of pS2 and total cathepsin D in primary breast cancer biopsies: their correlation with steroid receptors.
    Marsigliante S; Biscozzo L; Correale M; Paradiso A; Leo G; Abbate I; Dragone CD; Storelli C
    Br J Cancer; 1994 Mar; 69(3):550-4. PubMed ID: 8123486
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of ER, PR, MIB-1, pS2, and nuclear grade in FNA specimens of cT1 breast carcinomas: clinicopathological correlation.
    Angelidou E; Politi E; Sotiropoulou G; Poulianou E; Koutselini H
    Diagn Cytopathol; 2006 Aug; 34(8):547-52. PubMed ID: 16850494
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Exon 5 deletion variant estrogen receptor messenger RNA expression in relation to tamoxifen resistance and progesterone receptor/pS2 status in human breast cancer.
    Daffada AA; Johnston SR; Smith IE; Detre S; King N; Dowsett M
    Cancer Res; 1995 Jan; 55(2):288-93. PubMed ID: 7812959
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biochemical parameters for prognostic evaluation in patients with breast cancer.
    Gion M; Mione R; Pappagallo GL; Gatti C; Nascimben O; Sampognaro E; Meo S
    Anticancer Res; 1994; 14(2B):693-8. PubMed ID: 8010728
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Steroid receptors, pS2 and cathepsin D in early clinically node-negative breast cancer.
    Stonelake PS; Baker PG; Gillespie WM; Dunn JA; Spooner D; Morrison JM; Bundred NJ; Oates GD; Lee MJ; Neoptolemos JP
    Eur J Cancer; 1994; 30A(1):5-11. PubMed ID: 8142164
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Clinico-biological impact of pS2 positivity in estrogen receptor negative-infiltrating ductal carcinomas of the breast].
    Ruibal A; Arias J; del Río MC; San Román JM; Lapeña G; Pardo C; Tejerina A
    Rev Esp Med Nucl; 2000 Oct; 19(6):428-33. PubMed ID: 11060273
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inflammatory breast carcinoma: an immunohistochemical study using monoclonal anti-pHER-2/neu, pS2, cathepsin, ER and PR.
    Charpin C; Bonnier P; Khouzami A; Vacheret H; Andrac L; Lavaut MN; Allasia C; Piana L
    Anticancer Res; 1992; 12(3):591-7. PubMed ID: 1352440
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunohistochemistry of pS2 in normal human breast and in various histological forms of breast tumours.
    Pallud C; Le Doussal V; Pichon MF; Prud'homme JF; Hacene K; Milgrom E
    Histopathology; 1993 Sep; 23(3):249-56. PubMed ID: 8225243
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Correlation between pS2 protein positivity, steroid receptor status and other prognostic factors in breast cancer.
    Racca S; Conti G; Pietribiasi F; Stramignoni D; Tampellini M; Valetto MR; Ghezzo F; Di Carlo F
    Int J Biol Markers; 1995; 10(2):87-93. PubMed ID: 7561244
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression of pS2 protein in breast cancer.
    Crombach G; Ingenhorst A; Göhring UJ; Scharl A; Neuhaus W; Möbus V; Schaeffer HJ
    Arch Gynecol Obstet; 1993; 253(4):183-92. PubMed ID: 8161252
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunohistochemical and biochemical analysis of the oestrogen regulated protein pS2, and its relation with oestrogen receptor and progesterone receptor in breast cancer.
    Detre S; King N; Salter J; MacLennan K; McKinna JA; Dowsett M
    J Clin Pathol; 1994 Mar; 47(3):240-4. PubMed ID: 8163696
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Expression of epidermal growth factor receptor (EGFR) in hormone-independent breast cancers].
    Ruibal A; Garrido-Pumar M; Arias JI
    Rev Esp Med Nucl; 2006; 25(1):15-9. PubMed ID: 16540006
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic relevance of pS2 status in association with steroid receptor status and proliferative activity in node-negative breast cancer.
    Cappelletti V; Coradini D; Scanziani E; Benini E; Silvestrini R; Di Fronzo G
    Eur J Cancer; 1992; 28A(8-9):1315-8. PubMed ID: 1515241
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.